Archive: דוד שי, CC BY-SA 4.0.
Teva has completed a $57.5 million upfront purchase of BioXcel Therapeutics’ neuroscience assets, adding worldwide rights to an investigational at-home agitation treatment and the approved medicine Igalmi, according to the company’s October 27 announcement.
The transaction includes up to $67.5 million in additional contingent payments. Teva said those payments include time-based amounts linked to regulatory approval, including possible approval delays, and amounts tied to sales milestones. They are not all guaranteed payments at closing.
The deal was completed through a court-supervised asset sale under Section 363 of the U.S. Bankruptcy Code. Teva stressed that it is buying assets, not acquiring BioXcel Therapeutics itself.
At-home use remains under FDA review
The main development asset, BXCL501, is an orally dissolving film containing dexmedetomidine. It is under FDA review for potential at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults, according to Teva.
That proposed use is not yet approved. The purchase transfers rights to the program; it does not settle the regulatory decision or authorize patients to use the product at home.
Teva said the application was filed as a supplemental New Drug Application to the existing application for Igalmi, an FDA-approved dexmedetomidine sublingual film for agitation associated with those disorders in a hospital setting. Worldwide rights to Igalmi are also included in the acquired assets.
The distinction matters for patients and clinicians: an existing hospital treatment and a proposed at-home indication have different regulatory status. Teva describes BXCL501 as investigational for the home setting, with any commercial opportunity dependent on FDA approval.
A completed asset deal, with future milestones
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries, acquired the assets after being selected as the successful bidder. The company said the transaction closed following bankruptcy-court approval and satisfaction of other closing conditions.
Teva framed the acquisition as part of its effort to expand its innovative neuroscience pipeline through outside development programs. Executive Vice President of Business Development Evan Lippman said the program fits the company’s focus on differentiated, late-stage opportunities.
The medical rationale is earlier intervention when agitation develops outside a health-care facility. Teva’s chief medical officer, Eric Hughes, said an approved at-home option could allow adults to address symptoms before they become more difficult to manage. That is the company’s intended benefit, not a finding that the proposed indication has received regulatory clearance.
The announcement does not give an FDA decision date or a launch date for at-home treatment. It also does not announce new clinical trial results. The immediate news is the completed transfer of the assets and their financial terms; the next clinical-commercial step remains the pending regulatory review.
JBizNews Desk | Tel Aviv
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
